Granite Point Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
– Sell
-40,000
Closed -$745K – 156
2021
Q3
$745K Sell
40,000
-10,000
-20% -$190K 0.06% 104
2021
Q2
$1.06M Buy
+50,000
New +$1.15M 0.04% 115

Other funds holding TSHA

Granite Point Capital Management's TSHA Position: Q4 2021 in Review

Granite Point Capital Management sold out of Taysha Gene Therapies (TSHA) in Q4 2021, closing a stake of 40,000 shares — an estimated $745K sold.

Granite Point Capital Management first reported a position in TSHA in Q2 2021 and held it in 2 quarters. The position peaked at $1.06M in Q2 2021. 65 funds tracked by Wall St. Rank hold TSHA as of Q4 2021.

  • Granite Point Capital Management reported no remaining Taysha Gene Therapies position as of Q4 2021 after selling out during the quarter.
  • Granite Point Capital Management sold 40,000 Taysha Gene Therapies shares in Q4 2021, an estimated $745K.
  • Granite Point Capital Management first reported a position in Taysha Gene Therapies in Q2 2021 and held it in 2 quarters.
  • Granite Point Capital Management's Taysha Gene Therapies position peaked at $1.06M in Q2 2021.
  • 65 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q4 2021.

Based on Granite Point Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.